[Skip to Content]
[Skip to Content Landing]
JAMA Ophthalmology Clinical Challenge
April 2018

Persistent Angiographic Abnormalities After Intravitreal Anti–Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity

Author Affiliations
  • 1Department of Ophthalmology, Weill Cornell Medical College, New York, New York
  • 2Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago
  • 3Center for Global Health, College of Medicine, University of Illinois at Chicago, Chicago
JAMA Ophthalmol. 2018;136(4):436-437. doi:10.1001/jamaophthalmol.2017.4172

A female patient with a history of premature birth (24 weeks’ gestational age, 538 g) and zone I, stage 3 retinopathy of prematurity (ROP) with plus disease treated with a single injection of 0.625 mg of intravitreal bevacizumab in each eye presented for routine examination at 2 years of age. Examination with the patient under anesthesia with fluorescein angiography (Figure 1) revealed significant peripheral retinal avascularity, circumferential vascular loops at the border of vascular and avascular retina, and arteriovenous anastomoses in both eyes. There was no evidence of retinal neovascularization or recurrence of ROP.

×